Therefore, we suggest that GALNT5 may affect FOLFIRINOX chemotherapy sensitivity in pancreatic cancer cells primarily by affecting the HR repair pathway during DDR (Fig. 4F) Considering that HR repair occurs mainly between the S or G2 phases of the cell cycle, this result is consistent with our previous detection of cell cycle changes (Fig. 3E-F). Here, GALNT5 is linked to familial pancreatic carcinoma.